Go Pro

This company recently went public with an IPO on Wednesday, August 5th 2026. They issued 17,000,000 shares at $15.00 - $17.00 per share. We will continue to update data for ATTO as it becomes available.

Attovia Therapeutics (ATTO) 10K Form and Latest SEC Filings 2026

$20.17 -0.21 (-1.03%)
Closing price 04:00 PM Eastern
Extended Trading
$20.22 +0.05 (+0.25%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Attovia Therapeutics SEC Filings & Recent Activity

Attovia Therapeutics (NASDAQ:ATTO) has submitted 32+ documents to the U.S. Securities and Exchange Commission (SEC) since 2026. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 4 submitted on August 7, 2026.

Form 4
Attovia Therapeutics, Inc. Reports Ownership Change on Aug. 7, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

Attovia Therapeutics SEC Filing History

Browse Attovia Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
08/07/2026 2:45 PM
Attovia Therapeutics (2058707) Issuer
Sanofi (1121404) Reporting
Sanofi (1121404) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/06/2026 4:11 PM
Attovia Therapeutics (2058707) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/06/2026 4:13 PM
Attovia Therapeutics (2058707) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/06/2026 4:14 PM
Attovia Therapeutics (2058707) Issuer
Chen Hubert (2142262) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/06/2026 4:35 PM
Attovia Therapeutics (2058707) Issuer
FHMLS XI, L.L.C. (1911623) Reporting
FHMLS XI, L.P. (1911580) Reporting
Frazier Life Sciences XI, L.P. (1911592) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/06/2026 4:15 PM
Attovia Therapeutics (2058707) Issuer
Veiby Petter (2141655) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/06/2026 4:16 PM
Attovia Therapeutics (2058707) Issuer
Odrowaz Zaneta (2141590) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/06/2026 4:17 PM
Attovia Therapeutics (2058707) Issuer
GOLD MITCHELL (1242882) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/06/2026 4:17 PM
Attovia Therapeutics (2058707) Issuer
You Angie (1647664) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/05/2026 6:19 PM
Alamar HoldCo, LLC (2148983) Reporting
Attovia Therapeutics (2058707) Issuer
Form 3
Initial statement of beneficial ownership of securities  
08/05/2026 5:13 PM
Attovia Therapeutics (2058707) Issuer
WALSH COLIN (1866174) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/04/2026 11:15 PM
Attovia Therapeutics (2058707) Filer
Form EFFECT
08/04/2026 8:00 PM
Attovia Therapeutics (2058707) Issuer
Deep Track Biotechnology Master Fund, Ltd. (2015536) Reporting
Deep Track Capital, LP (1856083) Reporting
KROIN DAVID (1397513) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/04/2026 7:42 PM
Attovia Therapeutics (2058707) Issuer
Green Jeremy (1650527) Reporting
Redmile Biopharma Investments III, L.P. (1838746) Reporting
Redmile Group, LLC (1425738) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/04/2026 7:00 PM
Attovia Therapeutics (2058707) Issuer
Vida Ventures GP III, L.L.C. (1855502) Reporting
Vida Ventures III, L.P. (1855504) Reporting
Vida Ventures III-A, L.P. (1855503) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/04/2026 6:38 PM
Attovia Therapeutics (2058707) Issuer
You Angie (1647664) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/04/2026 6:41 PM
Attovia Therapeutics (2058707) Issuer
venBio Global Strategic Fund IV, L.P. (1862109) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/04/2026 6:28 PM
Attovia Therapeutics (2058707) Issuer
Smither John W (1559583) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/04/2026 6:30 PM
Attovia Therapeutics (2058707) Issuer
Chen Hubert (2142262) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/04/2026 6:30 PM
Attovia Therapeutics (2058707) Issuer
Topper James N (1341382) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/04/2026 6:31 PM
Attovia Therapeutics (2058707) Issuer
GOLD MITCHELL (1242882) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/04/2026 6:31 PM
Attovia Therapeutics (2058707) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/04/2026 6:33 PM
Attovia Therapeutics (2058707) Issuer
Odrowaz Zaneta (2141590) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/04/2026 6:34 PM
Attovia Therapeutics (2058707) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/04/2026 6:34 PM
Attovia Therapeutics (2058707) Issuer
Royston Aaron (1727703) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/04/2026 6:36 PM
Attovia Therapeutics (2058707) Issuer
Veiby Petter (2141655) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/04/2026 6:03 PM
Attovia Therapeutics (2058707) Issuer
Broad Street Principal Investments, L.L.C. (1575993) Reporting
GOLDMAN SACHS & CO. LLC (769993) Reporting
GOLDMAN SACHS ASSET MANAGEMENT, L.P. (1229262) Reporting
GOLDMAN SACHS GROUP INC (886982) Reporting
West Street Life Sciences I, L.P. (1951154) Reporting
WSLS EMP OFFSHORE INVESTMENTS, L.P. (2148329) Reporting
WSLS EMP ONSHORE INVESTMENTS, L.P. (2148331) Reporting
WSLS OFFSHORE INVESTMENTS, SLP (2148330) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/04/2026 5:33 PM
Attovia Therapeutics (2058707) Issuer
FHMLS XI, L.L.C. (1911623) Reporting
FHMLS XI, L.P. (1911580) Reporting
Frazier Life Sciences XI, L.P. (1911592) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/04/2026 11:39 AM
Attovia Therapeutics (2058707) Filer
Form CERT
08/04/2026 5:59 AM
Attovia Therapeutics (2058707) Filer
Form S-1/A
07/14/2026 3:32 PM
Attovia Therapeutics (2058707) Filer
Form S-1
Registration statement under Securities Act of 1933  
(Data available from 1/1/2016 forward)

Attovia Therapeutics SEC Filings - Frequently Asked Questions

Attovia Therapeutics (ATTO) has submitted 32+ filings to the SEC since 2026. You can browse the complete history or filter by form type using the tools above.

The most recent filing was a Form 4 submitted on August 7, 2026. This was an insider ownership change filed by 4 - Attovia Therapeutics, Inc. (0002058707) (Issuer).

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:ATTO) was last updated on 8/7/2026 by MarketBeat.com Staff.
From Our Partners